NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD
1.31
+0.07 (+5.65%)
The current stock price of FATE is 1.31 USD. In the past month the price increased by 92.65%. In the past year, price decreased by -67.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
FATE THERAPEUTICS INC
12278 Scripps Summit Drive
San Diego CALIFORNIA 92121 US
CEO: J. Scott Wolchko
Employees: 181
Company Website: https://fatetherapeutics.com/
Investor Relations: https://ir.fatetherapeutics.com/
Phone: 18588751803
The current stock price of FATE is 1.31 USD. The price increased by 5.65% in the last trading session.
The exchange symbol of FATE THERAPEUTICS INC is FATE and it is listed on the Nasdaq exchange.
FATE stock is listed on the Nasdaq exchange.
19 analysts have analysed FATE and the average price target is 6.52 USD. This implies a price increase of 397.46% is expected in the next year compared to the current price of 1.31. Check the FATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FATE THERAPEUTICS INC (FATE) has a market capitalization of 150.13M USD. This makes FATE a Micro Cap stock.
FATE THERAPEUTICS INC (FATE) currently has 181 employees.
FATE THERAPEUTICS INC (FATE) has a support level at 1.31 and a resistance level at 1.38. Check the full technical report for a detailed analysis of FATE support and resistance levels.
The Revenue of FATE THERAPEUTICS INC (FATE) is expected to decline by -66.7% in the next year. Check the estimates tab for more information on the FATE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FATE does not pay a dividend.
FATE THERAPEUTICS INC (FATE) will report earnings on 2025-05-07, after the market close.
FATE THERAPEUTICS INC (FATE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).
The outstanding short interest for FATE THERAPEUTICS INC (FATE) is 14.12% of its float. Check the ownership tab for more information on the FATE short interest.
ChartMill assigns a technical rating of 3 / 10 to FATE. When comparing the yearly performance of all stocks, FATE is a bad performer in the overall market: 86.85% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FATE. While FATE has a great health rating, there are worries on its profitability.
Over the last trailing twelve months FATE reported a non-GAAP Earnings per Share(EPS) of -1.64.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.27% | ||
ROE | -58.44% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 75% to FATE. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 5.51% and a revenue growth -66.7% for FATE